Insulet Corporation risk profile
39 Normal where most of the sector sits
Measured 21 October 2026 from PODD's filed statements. Recomputed nightly.
39 (Normal), driven by Concentration at 69, over 7 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 64 | Stretched | Volatile | Drawdown from the 52-week high — 59.0% |
| Operating pressure | 19 | Contained | Easing | Costs outgrowing revenue — -4.0 percentage points |
| Cash conversion | 15 | Contained | Easing | Capital spending against operating cash — 0.34x |
| Leverage and coverage | 14 | Contained | Stable | Interest cover — 9.50x |
| Competitive position | 32 | Normal | Stable | Operating-margin gap against peers — +5.6 percentage points |
| Concentration | 69 | Stretched | Stable | Geographic concentration — 5,205 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Insulet Corporation